NASD · Healthcare · Biotechnology · USA
Axsome Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Axsome Therapeutics is a biopharmaceutical company developing medicines for central nervous system conditions. The company markets three FDA-approved products: AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for acute migraine treatment. It also maintains a pipeline of investigational candidates, including AXS-05 for Alzheimer's disease agitation and smoking cessation, and solriamfetol for various neurological and psychiatric disorders.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Axsome Therapeutics Inc stock.
Overvalued: intrinsic value $72.31 per share, market price $135.95, margin of safety -88.0% (as of 2026-11-17).
A 4.2x revenue multiple, discounted for its losses, values the shares at $72.31; the price of $135.95 is 88% above that value.
17 more funds hold it; the full list is part of the paid plan.
50 more in this industry show a wider margin of safety.
AXSM is overvalued (as of the 2026-11-17 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $72.31; the price of $135.95 is 88% above that value.
$72.31 per share (as of the 2026-11-17 close), against a market price of $135.95. That is a margin of safety of -88.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.